The ARF1 Knockout HeLa Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from HeLa cells, engineered to disrupt the human ARF1 gene. This polyclonal model provides a loss-of-function system for interrogating ARF1-dependent cellular processes without clonal isolation artifacts. The pooled editing enables researchers to assess population-level responses while maintaining the heterogeneous advantages of polyclonal populations.
The parental HeLa cell line originates from an aggressive human cervical adenocarcinoma and contains integrated human papillomavirus 18 (HPV-18) DNA. The viral oncoproteins E6 and E7 inactivate the tumor suppressors p53 and Rb, conferring high proliferative capacity and tumorigenicity. HeLa cells are a foundational model for human cervical cancer and cell biology, with a well-characterized epithelial phenotype and extensive use in trafficking, signaling, and cancer research.
ARF1 encodes a small GTPase cycling between GDP- and GTP-bound states, regulated by GEFs including GBF1, BIG1, BIG2, and cytohesins. GTP-bound ARF1 recruits the COPI coatomer (??-COP, ??-COP, ??-COP, ??-COP, ??-COP) to Golgi membranes for retrograde transport. It also interacts with GGA1, GGA2, GGA3, and AP-1 for cargo sorting. Downstream, ARF1 activates phospholipase D1/D2 and PI4KIII??, producing phosphatidic acid and phosphoinositides that remodel actin via cortactin and the WAVE regulatory complex. These activities govern Golgi structure, membrane trafficking, and cell migration.
In the HeLa context, ARF1 disruption significantly alters Golgi organization and secretory pathway dynamics. Given HeLa??s reliance on robust membrane trafficking for proliferation and its HPV-driven oncogenic signaling, ARF1 knockout disrupts retrograde transport, integrin-mediated adhesion, and actin cytoskeleton reorganization. This model is particularly valuable for studying Golgi apparatus dysfunction, cancer metastasis, and viral replication dependence on host trafficking machinery. The polyclonal nature captures a range of editing events, enabling dose-response studies in a genetically defined background.
Researchers can utilize this knockout model for functional analysis of retrograde transport using the VSVG-GFP assay, immunofluorescence-based Golgi morphology assessment with GM130 or giantin, and quantitative expression profiling via western blot and RT-qPCR. The cells are suited for inhibitor screening (Brefeldin A, golgicide A) and migration/invasion assays (Transwell, wound healing). Co-immunoprecipitation and phospholipase D activity assays enable signaling studies, while flow cytometry permits integrin surface analysis. For inquiries or technical support regarding this product, please contact Ascent Research.
